Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
Status:
Withdrawn
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in
patients with a certain type of large B-Cell Lymphoma. The side effects (unwanted effects) of
SGN-35 in patients with this certain type of large B-Cell Lymphoma will also be studied. It
is not known if brentuximab vedotin is better or worse than other treatment that might be
given.
Phase:
N/A
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute